|
|
NAT2基因多态性与异烟肼血药浓度关系的研究
|
Abstract:
目的：通过对肺结核患者进行异烟肼血药浓度监测，以及NAT2基因多态性检测，探讨NAT2基因多态性与异烟肼血药浓度之间的关系。方法：研究对象为昆明市第三人民医院2020年结核科诊断为初治肺结核的患者，共纳入62例，规律口服异烟肼5天，用药后2 h采外周静脉血检测其血药浓度，同时提取DNA，用Sanger法进行NAT2基因多态性分析；SPSS 22 Pearson相关性分析影响异烟肼血药浓度的因素(包括性别、年龄、体重、NAT2基因多态性)。结果：性别、年龄、体重与异烟肼血药浓度不具有相关性，而NAT2代谢型异烟肼血药浓度具有相关性；62例患者中，NAT2快代谢型22例(35.5%)，中间代谢型29例(46.8%)，慢代谢型11例(17.7%)；11例慢代谢型患者中，NAT2*6A*6A有6例，占比54.5%，NAT2*7B*7B有4例，占比36.4%，NAT2*5B*5B有1例，占比9.1%。Pearson相关性分析提示，NAT2基因多态性与异烟肼血药浓度具有相关性，P = 0.03。结论：NAT2*6A*6A与NAT2*7B*7B基因型可能为主要的NAT2慢代谢型，携带该等位基因的患者易导致异烟肼血药浓度偏高；NAT2基因多态性与异烟肼血药浓度具有相关性。NAT2基因多态性是影响异烟肼血药浓度的重要因素之一，临床在使用异烟肼时可根据NAT2基因多态性调整用药剂量，同时监测其血药浓度以达到更精准的治疗方案。
Objective: The relationship between NAT2 gene polymorphism and isoniazid drug concentration in blood was investigated by monitoring isoniazid drug concentration in blood and detecting NAT2 gene polymorphism in patients with pulmonary tuberculosis. Methods: A total of 62 patients diagnosed with newly treated tuberculosis in the tuberculosis Department of Kunming Third People’s Hospital in 2020 were included in the study. Isoniazid was taken orally for 5 days, and peripheral venous blood was collected 2 hours after administration to detect the drug concentration in blood. Meanwhile, DNA was extracted and NAT2 gene polymorphism was analyzed by the Sanger method. SPSS 22 Pearson correlation analysis was performed to analyze the factors influencing isoniazid drug concentration in blood (including sex, age, weight, NAT2 gene polymorphism). Results: There was no correlation between sex, age and body weight and isoniazid drug concentration in blood, but there was a correlation between NAT2 metabolism isoniazid drug concentration in blood. Among the 62 patients, there were 22 NAT2 fast metabolizers (35.5%), 29 NAT2 intermediate metabolizers (46.8%) and 11 NAT2 slow metabolizers (17.7%). Among the 11 patients with slow metabolism, there were 6 cases of NAT2*6A*6A, accounting for 54.5%, 4 cases of NAT2*7B*7B, accounting for 36.4%, and 1 case of NAT2*5B*5B, accounting for 9.1%. Pearson correlation analysis showed that the polymorphism of NAT2 gene was correlated with isoniazid drug concentration in blood (P = 0.03). Conclusions: The NAT2*6A*6A and NAT2*7B*7B genotypes may be the main slow metabolizers of NAT2, and patients carrying this allele are prone to high drug concentration in blood of isoniazid. There was a correlation between NAT2 gene
| [1] | 罗一婷, 翁榕星, 等. 2019 WHO全球结核报告: 全球与中国关键数据分析[J]. 新发传染病电子杂志, 2020, 5(1): 47-50. |
| [2] | 高静韬, 刘宇红. 2020年世界卫生组织全球结核病报告要点解读[J]. 河北医科大学学报, 2021, 42(1): 1-6. |
| [3] | 中国防痨协会. 耐药结核病化学治疗指南(2019年简版) [J]. 中国防痨杂志, 2019, 41(10): 1025-1073. |
| [4] | 刘诚诚, 金海霞, 徐建, 等. 结核病患者N-乙酰基转移酶2基因型与异烟肼血药浓度关系的研究[J]. 中国防涝杂志, 2013(3): 179-182. |
| [5] | 中华人民共和国国家卫生和计划生育委员会. 国家卫生计生委医政医管局关于印发《药物代谢酶和药物作用靶点基因检测技术指南(试行)》和《肿瘤个体化治疗检测技术指南(试行)》的通知, 国卫医医护便函[2015]240号[Z]. 2015-07-29. |
| [6] | Huang, Y. (2014) Recent Progress in Genetic Variation and Risk of Antituberculosis Drug-Induced Liver Injury. Journal of the Chinese Medical Association, 77, 169-173. https://doi.org/10.1016/j.jcma.2014.01.010 |
| [7] | Chen, B., Cai, W., Li, J. and Cao, X. (2009) Estimating N-Acetyltransferase Metabolic Activity and Pharmacokinetic Parameters of Isoniazid from Genotypes in Chinese Subjects. Clinica Chimica Acta, 405, 23-29. https://doi.org/10.1016/j.cca.2009.03.045 |
| [8] | Chen, B., Cao, X. and Li, J. (2011) Gene Dose Effect of NAT2 Variants on the Pharmacokinetics of Isoniazid and Acetylisoniazid in Healthy Chinese Subjects. Drug Metabolism and Drug Interactions, 26, 113-118. https://doi.org/10.1515/dmdi.2011.016 |
| [9] | 首都医科大学附属北京胸科医院《中国防痨杂志》编辑委员会. 结核病患者N-乙酰基转移酶2编码基因多态性检测与异烟肼合理用药专家共识[J]. 中国防痨杂志, 2021, 43(11): 1107-1112. |
| [10] | McDonagh, E.M., Boukouvala, S., Aklillu, E., Hein, D.W., Altman, R.B. and Klein, T.E. (2014) PharmGKB Summary: Very Important Pharmacogene Information for N-Acetyltransferase 2. Pharmacogenetics and Genomics, 24, 409-425. https://doi.org/10.1097/fpc.0000000000000062 |
| [11] | 陈亮亮, 胡文豪, 刘魁, 等. N-乙酰基转移酶2基因多态性与膀胱癌的易感性在亚洲人群中的Meta分析[J]. 临床泌尿外科杂志, 2014, 29(2): 118-124. |
| [12] | Chen, H., Cao, Y., Hu, W., Liu, X., Liu, Q., Zhang, J., et al. (2006) Genetic Polymorphisms of Phase II Metabolic Enzymes and Lung Cancer Susceptibility in a Population of Central South China. Disease Markers, 22, 141-152. https://doi.org/10.1155/2006/436497 |
| [13] | Quan, L., Chattopadhyay, K., Nelson, H.H., Chan, K.K., Xiang, Y., Zhang, W., et al. (2016) Differential Association for n-Acetyltransferase 2 Genotype and Phenotype with Bladder Cancer Risk in Chinese Population. Oncotarget, 7, 40012-40024. https://doi.org/10.18632/oncotarget.9475 |
| [14] | Zhang, M., Wang, S., Wilffert, B., Tong, R., van Soolingen, D., van den Hof, S., et al. (2018) The Association between the NAT2 Genetic Polymorphisms and Risk of DILI during Anti‐TB Treatment: A Systematic Review and Meta‐Analysis. British Journal of Clinical Pharmacology, 84, 2747-2760. https://doi.org/10.1111/bcp.13722 |
| [15] | Hein, D.W. and Millner, L.M. (2020) Arylamine N-Acetyltransferase Acetylation Polymorphisms: Paradigm for Pharmacogenomic-Guided Therapy—A Focused Review. Expert Opinion on Drug Metabolism & Toxicology, 17, 9-21. https://doi.org/10.1080/17425255.2021.1840551 |
| [16] | Walker, K., Ginsberg, G., Hattis, D., Johns, D.O., Guyton, K.Z. and Sonawane, B. (2009) Genetic Polymorphism in n-Acetyltransferase (NAT): Population Distribution of NAT1 and NAT2 Activity. Journal of Toxicology and Environmental Health, Part B, 12, 440-472. https://doi.org/10.1080/10937400903158383 |
| [17] | 王宁, 郑璐瑶, 孟秀娟, 等. 中国人群N-乙酰基转移酶2基因型分布特征及不同基因分型方法的比较[J]. 中国防痨杂志, 2022, 44(6): 625-634. |
| [18] | Zhang, D., Hao, J., Hou, R., Yu, Y., Hu, B. and Wei, L. (2019) The Role of NAT2 Polymorphism and Methylation in Anti‐Tuberculosis Drug‐Induced Liver Injury in Mongolian Tuberculosis Patients. Journal of Clinical Pharmacy and Therapeutics, 45, 561-569. https://doi.org/10.1111/jcpt.13097 |
| [19] | Araujo-Mariz, C., Militão de Albuquerque, M.d.F.P., Lopes, E.P., Ximenes, R.A.A., Lacerda, H.R., Miranda-Filho, D.B., et al. (2020) Hepatotoxicity during TB Treatment in People with HIV/AIDS Related to NAT2 Polymorphisms in Pernambuco, Northeast Brazil. Annals of Hepatology, 19, 153-160. https://doi.org/10.1016/j.aohep.2019.09.008 |
| [20] | 许飞虹. 结核病患者NAT2基因型、四种抗结核药物血浆浓度及其肝功能之间的相关性研究[D]: [硕士学位论文]. 张家口: 河北北方学院, 2014: 19-29. |
| [21] | Singh, N., Dubey, S., Chinnaraj, S., Golani, A. and Maitra, A. (2009) Study of NAT2 Gene Polymorphisms in an Indian Population: Association with Plasma Isoniazid Concentration in a Cohort of Tuberculosis Patients. Molecular Diagnosis & Therapy, 13, 49-58. https://doi.org/10.1007/bf03256314 |
| [22] | 张敏, 徐娜, 李星星, 等. NAT2基因多态性与抗结核药物血药浓度相关性分析[J]. 成都医学院学报, 2022, 17(3): 311-315. |
| [23] | 张亮, 冯枭, 林霏申, 等. 异烟肼血药浓度的影响因素分析[J]. 药学与临床研究, 2018, 26(6): 1-4. |
